Invivyd Gets FDA Emergency Use Approval to Prevent Covid-19 in Immunocompromised Adolescents, Adults
By Sabela Ojea
Invivyd said the U.S. Food and Drug Administration granted emergency use authorization to its Pemgarda monoclonal antibody to prevent Covid-19 in immunocompromised adolescents and adults.
The biotechnology company on Friday said that the authorization of Pemgarda, administered as an intravenous infusion, targets people aged at least 12 weighing at least 40 kilograms, or about 88 pounds.
Recipients shouldn't be infected with the Covid or have had a recent exposure to an individual infected with the virus ahead of the intravenous infusion, Invivyd said.
The company said people who are immunocompromised continue to be disproportionally affected by Covid, even after receiving multiple vaccine doses.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
March 22, 2024 15:41 ET (19:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth